$16.65
-0.56-3.25%
Last update: Oct 30, 4:24 PM
Aurinia Pharmaceuticals Inc (AUPH) Stock Price, Quote, News & History
AUPHNASDAQ
Aurinia Pharmaceuticals shares rise after settling patent litigation with Teva, which can launch generic voclosporin no earlier than December 2036.
You can purchase shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) through any online brokerage.
Other companies in Aurinia Pharmaceuticals’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Aurinia Pharmaceuticals has a consensus price target of $15.86.
The stock price for Aurinia Pharmaceuticals (NASDAQ: AUPH) is $16.68 last updated October 30, 2026 at 4:24 PM EDT.
There are no upcoming dividends for Aurinia Pharmaceuticals.
Aurinia Pharmaceuticals does not have any upcoming earnings scheduled.
There is no upcoming split for Aurinia Pharmaceuticals.
Aurinia Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for...
